Several gangliosides, particularly GD1b, GD2, GD3, GM2, and GM3, have been identified as tumor-associated antigens and exhibit elevated expression in tumor cells. As a result, an investigational therapeutic approach that is showing great potential is the use of ganglioside antibodies to target cancer cells that express these gangliosides. Matreya’s ganglioside antibodies are directed against the carbohydrate chains of key glycolipids and are useful in the identification of gangliosides. All antibodies are quality tested by ELISA and TLC-based immunoblotting analysis.
Read full newsletter here